Amylyx Pharmaceuticals (AMLX) Finished Goods (2022)
Amylyx Pharmaceuticals (AMLX) posted Finished Goods of $937000.0 for Q4 2022, up 751.82% on a QoQ basis from $110000.0 in Q3 2022.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Finished Goods (2022) Analysis & Trends
Amylyx Pharmaceuticals has reported Finished Goods for 1 years, with the latest figure at $937000.0 in Q4 2022.
- On a quarterly basis, Finished Goods changed N/A year-over-year to $937000.0 in Q4 2022; TTM through Dec 2022 was $937000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $937000.0, changed N/A from the prior year.
- Finished Goods was $937000.0 for Q4 2022 at Amylyx Pharmaceuticals, up from $110000.0 in the prior quarter.
- The five-year high for Finished Goods was $937000.0 in Q4 2022, with the low at $110000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - |